全球骨质疏松症市场及药物分析:2010～2015年

全球骨质疏松症市场及药物分析:2010～2015年 是由出版商Renub Research在2011年09月所出版的。 这份英文市场调查报告书包含72 Pages 价格从美金950起跳。

简介

骨质疏松症是毫无徵兆，骨质慢慢减少的所谓「沈默的疾病」。全球骨质疏松症市场预计到2015年将达到160亿美金。目前市场上既有以及开发中的治疗法非常充实，因此预计今后此市场将大幅成长。

本报告提供全球骨质疏松症市场相关调查分析，4个药物类别相关市场占有率数据(2006～2014年)，与9个药物品牌相关的2007～2015年销售额与市场占有率，汇整各地区趋势，开发平台与未来发展预测，为您概述为以下内容。

第1章 摘要整理

第2章 全球骨质疏松症市场

第3章 全球骨质疏松症市场占有率(2007～2015年)

• 各级药物:骨质疏松症市场占有率与预测
• 各药物市场占有率:骨质疏松症市场占有率与预测
• 各国(美国，欧洲，日本，中国，印度，韩国):骨质疏松症市场占有率与预测

第4章 各国骨质疏松症市场及预测(2008～2015年)

• 美国市场及预测
• 欧洲市场及预测
• 日本市场及预测
• 中国市场及预测
• 韩国市场及预测
• 印度市场及预测

第5章 各类药物市场与预测(2004～2014年)

• 双磷酸盐
• 选择性雌激素受体调节剂（SERM)
• 副甲状腺素
• 降钙素

第6章 药物市场分析与预测(2004～2015年)

• 双磷酸盐市场及预测
  • Fosamax
  • Bonviva/Boniva
  • Reclast/Aclasta
  • Actone
• SERM药物市场及预测
  • Evista
  • Viviant/ Conbriza
• 副甲状腺素市场及预测
  • Forteo
• 抑钙素药物市场及预测
  • Miacalcin
• Prolia

第7章 骨质疏松症市场分析的开发平台分析

• Odanacatib (MK 0822)
• Aprela (Bazedoxifene)

第8章 骨质疏松症治疗药物市场专利契约(2008～2009年)

• 主要企业分析
• Eli Lilly
• Roche
• Amgen
• Merck
• Novartis
  • 收益
  • 优势
  • 弱点

图表

目录

Abstract

Market Overview

Osteoporosis is often called the “silent disease” because bone loss occurs without symptoms. It is characterized by low bone mass and micro-architectural deterioration of bone tissue, leading to bone fragility and a consequent increase in risk of fracture. Global osteoporosis market is expected to reach 16 Billion by 2015. This significant growth is primarily attributed to strong treatment options currently available in the market as well as strong pipeline products. The increase in the prevalence of osteoporosis among the female population is the principal driver of the osteoporosis market and will continue to be in the future.

Fosamax was the undisputed leading product in the history of global osteoporosis drug market till 2007. It has a market share of nearly 37% in 2007 but, declined to 5% by 2015 due to patent expiry and competition from cheaper generics. Boniva and Evista were leading the osteoporosis market till 2010 but the dynamics of osteoporosis market is expected to change by 2011 as Prolia is going to be introduced in the market. It is predicted that Prolia will lead the market with nearly 45% share by 2015.

The osteoporosis market offers multiple opportunities for current and future market players. In addition to increasing awareness, diagnosis and treatment, there is the need to develop new drugs that promote bone building. While the market awaits new growth, driven by the launch of several promising pipeline drugs, including Amgen' s Prolia (denosumab), companies are looking for innovative ways to maximize revenues from their products nearing the end of their lifecycles.

Report Details

“Global Osteoporosis Market & Drugs Analysis 2010 - 2015” report published by Renub Research provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally and features latest available data covering:

• Global Osteoporosis Market (2009 to 2015)
• Four Osteoporosis Drug Class (Bisphosphonate, SERM, PTH and Calcitonin) market and market share data of (2006 to 2014)
• Top Nine Osteoporosis Drug Brand (Fosamax, Actonel, Reclast, Boniva, Evista, Forteo, Viviant/Conbriza, Miacalcin, Prolia) sales and market share data of 2007 to 2015
• Six Countries (USA, European Union, Japan, China, India, Korea) Osteoporosis market share data of (2009 to 2015)
• Six Countries (USA, European Union, Japan, China, India, Korea) Osteoporosis market data of (2005 to 2015)
• Pipeline Developmental Agents (Odanacatib, Aprela) Future Trends
• Key Companies (Eli Lilly, Roche, Amgen, Merck & Novartis) Analysis - Revenue in Osteoporosis Market (2007 to 2010), Strength & Weakness in Osteoporosis Market

Research Highlights

• Global Osteoporosis drug market is expected to reach the figure of US$ 16 Billion by 2015
• United States Osteoporosis drug market was nearly US$ 5 Billion in 2010
• United States & China together is expected to control 61% market share in osteoporosis drug market by 2015
• Although SERM is increasing its market share year on year but Bisphosphonates will continue to dominate the osteoporosis drug class segment with 56% in 2014
• Prolia will lead the Osteoporosis drug market with 45% share by 2015

Data Sources

Information and data in this report has been collected from various printable and non-printable sources like Trade Journals, White papers, News websites, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 100 paid databases.

Table of Contents

1. Executive Summary

2. Global Osteoporosis Market

3. Global Osteoporosis Market Share (2007 - 2015)

• 3.1. By Drug Class - Osteoporosis Market Share & Forecast
• 3.2. By Drug Market Share - Osteoporosis Market Share & Forecast
• 3.3. By Country (USA, European Union, Japan, China, India, Korea) - Osteoporosis Drug Market Share & Forecast

4. By Country - Osteoporosis Market & Forecast (2008 - 2015)

• 4.1. United States Osteoporosis Market & Forecast
• 4.2. European Union Osteoporosis Market & Forecast
• 4.3. Japan Osteoporosis Market & Forecast
• 4.4. China Osteoporosis Market & Forecast
• 4.5. Korea Osteoporosis Market & Forecast
• 4.6. India Osteoporosis Market & Forecast

5. Osteoporosis Drugs Classes Market & Forecast (2004 - 2014)

• 5.1. Global Bisphosphonate Market & Forecast
• 5.2. Global Selective Estrogen Receptor Modulators (SERM) Market & Forecast
• 5.3. Global Parathyroid Hormone (PTH) Market & Forecast
• 5.4. Global Calcitonin Market & Forecast

6. Osteoporosis Drugs Market Analysis & Forecast (2004 - 2015)

• 6.1. Bisphosphonate Drugs Market & Forecast
  • 6.1.1. Fosamax (Alendronate)
  • 6.1.2. Bonviva/Boniva (Ibandronic Acid)
  • 6.1.3. Reclast/Aclasta
  • 6.1.4. Actonel (Risedronate)
• 6.2. SERMs Drugs Market & Forecast
  • 6.2.1. Evista (Raloxifene)
  • 6.2.2. Viviant/ Conbriza (Bazedoxifene)
• 6.3. Parathyroid Hormone Drugs Market & Forecast
  • 6.3.1. Forteo
• 6.4. Calcitonin Drugs Market & Forecast
  • 6.4.1. Miacalcin
• 6.5. Prolia (Denosumab)

7. Pipeline Drugs in Osteoporosis Market Analysis

• 7.1. Odanacatib (MK 0822)
• 7.2. Aprela (Bazedoxifene)

8. Licensing Deals in Osteoporosis Drug Market (2008 - 2009)

9. Key Companies Analysis

• 9.1. Eli Lilly
  • 9.1.1. Eli Lilly Revenue in Osteoporosis Segment
  • 9.1.2. Strength
  • 9.1.3. Weaknesses
• 9.2. Roche
  • 9.2.1. Roche Revenue in Osteoporosis Segment
  • 9.2.2. Strength
  • 9.2.3. Weaknesses
• 9.3. Amgen
  • 9.3.1. Strength
  • 9.3.2. Weaknesses
• 9.4. Merck
  • 9.4.1. Merck Revenue in Osteoporosis Segment
  • 9.4.2. Strength
  • 9.4.3. Weaknesses
• 9.5. Novartis
  • 9.5.1. Novartis Revenue in Osteoporosis Segment
  • 9.5.2. Strength
  • 9.5.3. Weaknesses

List of Figures:

• Figure 2 1: Global - Osteoporosis Market (Million US$), 2009 - 2010
• Figure 2 2: Global - Forecast for Osteoporosis Market (Million US$), 2011 - 2015
• Figure 3 1: Global - Osteoporosis Drug Class Market Share (Percent), 2006 - 2010
• Figure 3 2: Global - Forecast for Osteoporosis Drug Class Market Share (Percent), 2011 - 2014
• Figure 3 3: Global - Osteoporosis Drug Market Share (Percent), 2007 - 2010
• Figure 3 4: Global - Forecast for Osteoporosis Drug Market Share (Percent), 2011 - 2015
• Figure 3 5: Global - Osteoporosis Drug Market Share of (USA, European Union, Japan, China, India, Korea) (Percent), 2009 - 2010
• Figure 3 6: Global - Forecast for Osteoporosis Drug Market Share of (USA, European Union, Japan, China, India, Korea) (Percent), 2011 - 2015
• Figure 4 1: United States - Osteoporosis Market (Million US$), 2008 - 2010
• Figure 4 2: United States - Forecast for Osteoporosis Market (Million US$), 2011 - 2021
• Figure 4 3: European Union - Osteoporosis Market (Million US$), 2009 - 2010
• Figure 4 4: European Union - Forecast for Osteoporosis Market (Million US$), 2011 - 2015
• Figure 4 5: Japan - Osteoporosis Market (Billion Yen), 2001 - 2010
• Figure 4 6: Japan - Forecast for Osteoporosis Market (Billion Yen), 2011 - 2015
• Figure 4 7: China - Osteoporosis Market (Million US$), 2004 - 2010
• Figure 4 8: China - Forecast for Osteoporosis Market (Million US$), 2011 - 2015
• Figure 4 9: Korea - Osteoporosis Market (Million US$), 2001 - 2010
• Figure 4 10: Korea - Forecast for Osteoporosis Market (Million US$), 2011 - 2015
• Figure 4 11: India - Osteoporosis Market (Million INR), 2007 - 2010
• Figure 4 12: India - Forecast for Osteoporosis Market (Million INR), 2011 - 2015
• Figure 5 1: Global - Bisphosphonate Market (Million US$), 2004 - 2010
• Figure 5 2: Global - Forecast for Bisphosphonate Market (Million US$), 2011 - 2014
• Figure 5 3: Global - SERM Market (Million US$), 2004 - 2010
• Figure 5 4: Global - Forecast for SERM Market (Million US$), 2011 - 2014
• Figure 5 5: Global - PTH Market (Million US$), 2004 - 2010
• Figure 5 6: Global - Forecast for PTH Market (Million US$), 2011 - 2014
• Figure 5 7: Global - Calcitonin Market (Billion US$), 2004 - 2010
• Figure 5 8: Global - Forecast for Calcitonin Market (Billion US$), 2004 - 2010
• Figure 6 1: Global - Fosamax Drug Sales (Million US$), 2003 - 2010
• Figure 6 2: Global - Forecast for Fosamax Drug Sales (Million US$), 2011 - 2015
• Figure 6 3: Global - Boniva Drug Sales (Million US$), 2005 - 2010
• Figure 6 4: Global - Forecast for Boniva Drug Sales (Million US$), 2011 - 2015
• Figure 6 5: Global - Reclast/Aclasta Drug Sales (Million US$), 2007 - 2010
• Figure 6 6: Global - Forecast for Reclast/Aclasta Drug Sales (Million US$), 2011 - 2015
• Figure 6 7: Global - Actonel Drug Sales (Million US$), 2004 - 2010
• Figure 6 8: Global - Forecast for Actonel Drug Sales (Million US$), 2011 - 2013
• Figure 6 10: Global - Evista Drug Sales (Million US$), 2001 - 2010
• Figure 6 11: Global - Forecast for Evista Drug Sales (Million US$), 2011 - 2015
• Figure 6 12: Global - Viviant/Conbriza Drug Sales (Million US$), 2010 - 2015
• Figure 6 13: Global - Forteo Drug Sales (Million US$), 2003 - 2010
• Figure 6 14: Global - Forecast for Forteo Drug Sales (Million US$), 2011 - 2015
• Figure 6 15: Global - Miacalcin Drug Sales (Million US$), 2004 - 2010
• Figure 6 16: Global - Forecast for Miacalcin Drug Sales (Million US$), 2011 - 2015
• Figure 6 17: Global - Forecast for Prolia Drug (Million US$), 2010 - 2016
• Figure 7 1: Global - Forecast for Odanacatib Drug (Million US$), 2012 - 2015
• Figure 7 2: Global - Forecast for Aprela Drug Sales (Million US$), 2011 - 2015
• Figure 9 1: Eli Lilly - Osteoporosis Drug Revenue (Million US$), 2007 - 2010
• Figure 9 2: Roche - Osteoporosis Drug Revenue (Million US$), 2007 - 2010
• Figure 9 3: Merck - Osteoporosis Drug Revenue (Million US$), 2007 - 2010
• Figure 9 4: Novartis - Osteoporosis Drug Revenue (Million US$), 2007 - 2010

List of Tables:

• Table 6 1: Actonel (Eisai, P&G and Sanofi-Aventis) - Sales (Million US$), 2004 - 2013
• Table 6 2: Benet (Risedronate) - Sales (Million US$), 2004 - 2013
• Table 9 1: Osteoporosis - Drugs Cost Comparison (US$) in 1 Year

相关商品

骨头疾病治疗相关市场调查报告书

全球及中国的骨质疏松症治疗药物市场:市场规模·市场趋势·市场预测(2010-2015年)
Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015)
价格 : US $ 2395
出版日期 : 2012年01月

中国的骨质疏松症市场分析与预测(2007年～2015年)
China Osteoporosis Market Analysis and Forecast, 2007 - 2015
价格 : US $ 1500
出版日期 : 2012年01月

全球肌肉骨骼疾病治疗药物的市场(到2017年为止)
Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014
价格 : US $ 3500
出版日期 : 2012年01月

Renub Research发行的制药相关市场调查报告书

泰国的医疗旅游:游客数及市场规模的预测(～2015年)

Thailand Medical Tourist Arrivals, Medical Tourism Market & Forecast to 2015

价格 : US $ 800

出版日期 : 2012年04月

C型肝炎(HCV)市场预测及药物开发平台分析:～2016年

Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016

价格 : US $ 975

出版日期 : 2012年01月

全球流感疫苗市场:市场机会·课题·市场预测

Influenza Vaccine Market Opportunities and Challenges: Worldwide Forecast

价格 : US $ 1100

出版日期 : 2012年01月

Email Alert(Email 通知) - 最新市场调查报告书

GII 将每天定期更新最新市场调查报书信息，选择您有兴趣的市场分类，我们将用Email的方式让您收到最新讯息!